SecBot SecBot
SECBOTREPLAY Home › Report › IMNM

IMNM · Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs…

Immunome Inc. · 8-K filed May 12, 2026 at 16:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed May 12, 2026 at 16:05 ET

Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA submission for varegacestat in desmoid tumors is the key catalyst, with ASCO oral presentation and EU MAA planned. Cash runway into 2028 supports pipeline execution.

  • NDA submitted to FDA for varegacestat in desmoid tumors (April 2026)
  • Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026
  • Q1 2026 net loss $53.8M ($-0.48/share) vs consensus $-0.60, 20% beat
  • Cash and equivalents $582.7M, runway into 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access